Dyadic (AMEX:DIL)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Dyadic Charts. Click Here for more Dyadic Charts.](/p.php?pid=staticchart&s=A%5EDIL&p=8&t=15)
Dyadic International, Inc. (AMEX:DIL), a biotechnology
company, will report today at the Third Annual World Congress on
Industrial Biotechnology and Bioprocessing in Toronto, Canada, that it
has identified and tested highly effective enzyme mixtures for the
efficient conversion of renewable cellulosic biomass to ethanol. "We
are making meaningful strides toward the production of low-cost
ethanol from biomass," said Dr. Glenn Nedwin, Chief Science Officer of
Dyadic.
Dyadic scientist Marco Baez, Ph.D. will present results of an
internal study on Dyadic's proprietary cellulase and hemicellulase
mixes with strong saccharifying activity on a number of different
lignocellulosic feedstocks, including Douglas fir and cotton. In
addition, Dr. Baez will present data showing the results of an
internal study of two new highly active cellobiohydrolases isolated
from Dyadic's patented Chrysosporium lucknowense fungal strain (known
as C1), as well as a mixture of pure monocomponent enzymes, all of
which demonstrated an extremely high ability to convert different
cellulosic substrates to glucose, the critical raw material for the
production of ethanol.
"The key hurdles that must be overcome for the large-scale
commercial production of low-cost ethanol from renewable biomass are
to reduce the cost and increase the efficiency of the enzymes used to
extract glucose and other sugars from the cellulolytic feedstocks,"
Dr. Nedwin explained. "Dyadic has been a leader in the
saccharification of cellulosic substrates for more than a decade. The
results to be presented today show that we are making rapid progress
in the development of potent enzyme mixtures that work well in the
cellulosic ethanol application. Dyadic has filed a patent application
with the U.S. Patent Office for these new enzymes and mixtures
containing these enzymes. This is in addition to the Company's many
other patents already issued or pending which protect our technology
in this area."
Separately, Dyadic noted that in a recent publication (BC Saha and
M.A. Cotta, Biotech. Prog. 22:449-453, 2006), researchers at the U.S.
Department of Agriculture measured the efficiency of various
commercially available enzyme preparations (including Dyadic's
Viscostar 150L) on wheat straw pretreated with alkaline peroxide for
the extraction of glucose and other sugars. The authors of this study
stated that "unlike corn fiber hemicellulose, which is very resistant
to hydrolysis using commercial enzymes, wheat straw hemicellulose can
be easily hydrolyzed enzymatically by using a single xylanase
preparation (Viscostar) after alkaline peroxide treatment."
The Third Annual World Congress on Industrial Biotechnology and
Bioprocessing, taking place from July 11 to July 14, 2006 in Toronto,
Canada, hosted by the Biotechnology Industry Organization (BIO),
American Chemical Society, the National Agriculture Biotechnology
Council, the Agri-Food Innovation Forum, the Chemical Institute of
Canada, BIOTECanada and EuropaBIO, is the premiere gathering of
thought leaders, investors, researchers and business executives in
industrial biotechnology, bioenergy and bioprocessing.
About Dyadic
Dyadic International, Inc. is engaged in the development,
manufacture and sale of biological products using a number of
proprietary fungal strains to produce enzymes and other biomaterials,
principally focused on a system for protein production based on the
patented Chrysosporium lucknowense fungus, known as C1. Dyadic is
applying its technologies to produce enzymes for use in converting
various agricultural products (e.g. corn) and waste products (e.g.
switch grass, wheat straw, sugar cane bagasse, etc.) into fermentable
sugars, which can then be used in the production of traditional and
cellulosic ethanol as well as other products currently derived from
petroleum. Dyadic's C1 technology also is being developed to
facilitate the discovery, development and large-scale production of
human antibodies and other high-value therapeutic proteins. Dyadic
currently sells more than 45 liquid and dry enzyme products to more
than 200 industrial customers in approximately 50 countries for the
textile, pulp & paper and animal feed industries.
Cautionary Statement for Forward-Looking Statements
Certain statements contained in this press release are
"forward-looking statements." These forward-looking statements involve
risks and uncertainties that could cause our actual results,
performance or achievements to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. For a discussion of these risks and
uncertainties, please see our filings from time to time with the
Securities and Exchange Commission, which are available free of charge
on the SEC's web site at http://www.sec.gov, including our Annual
Report on Form 10-KSB for the year ended December 31, 2005, and our
Quarterly Report on Form 10-QSB for the quarter ended March 31, 2006.
Except as required by law, we expressly disclaim any intent or
obligation to update any forward-looking statements.